References
- Alexander GC, Gallagher SA, Mascola A, et al. (2011). Increasing off-label use of antipsychotic medications in the United States, 1995–2008. Pharmacoepidemiol Drug Saf, 20, 177–84
- APA. (2010). Practice guidleines for the treatment of patients with major depressive disorder. Available from: http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf [last accessed 20 Aug 2014]
- Deyo RA, Cherkin DC., Ciol MA. (1992). Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol, 45, 613–19
- Fava M. (2003). Diagnosis and definition of treatment-resistant depression. Biol Psychiatry, 53, 649–59
- Fullerton CA, Busch AB, Normand SL, et al. (2011). Ten-year trends in quality of care and spending for depression: 1996 through 2005. Arch Gen Psychiatry, 68, 1218–26
- Gibson TB, Jing Y, Smith Carls G, et al. (2010). Cost burden of treatment resistance in patients with depression. Am J Manag Care, 16, 370–7
- Halpern R, Nadkarni A, Kalsekar I, et al. (2013). Medical costs and hospitalizations among patients with depression treated with adjunctive atypical antipsychotic therapy: An analysis of health insurance claims data. Ann Pharmacother, 47, 933–45
- Jing Y, Kalsekar I, Curkendall SM, et al. (2011). Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression. Clin Ther, 33, 1246–57
- Kessler RC, Berglund P, Demler O, et al. (2003). The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA, 289, 3095–105
- Kessler RC, Sonnega A, Bromet E, et al. (1995). Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry, 52, 1048–60
- McDonagh M, Peterson K, Carson S, et al. (2010). Drug class review: Atypical antipsychotic drugs. Update 3
- Nadkarni A, Kalsekar I, You M, et al. (2013). Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy. Clinicoecon Outcomes Res, 5, 49–57
- Narasimhan M, Raynor JD, Jones AB. (2008). Depression in the medically ill: Diagnostic and therapeutic implications. Curr Psychiatry Rep, 10, 272–9
- NGC. (2012). Diagnosis and treatment of depression in adults: 2012 clinical practice guideline. National Guideline Clearinghouse. Available from: http://www.guideline.gov/content.aspx?id=39432 [last accessed 09 Oct 2015]
- Olfson M, Marcus SC, Druss B, et al. (2002). National trends in the outpatient treatment of depression. JAMA, 287, 203–9
- Petersen T, Papakostas GI, Posternak MA, et al. (2005). Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol, 25, 336–41
- Shelton RC, Osuntokun O, Heinloth AN, Corya SA. (2010). Therapeutic options for treatment-resistant depression. CNS Drugs, 24, 131–61
- Spielmans GI, Berman MI, Linardatos E, et al. (2013). Adjunctive atypical antipsychotic treatment for major depressive disorder: A meta-analysis of depression, quality of life, and safety outcomes. PLoS Med, 10, e1001403
- Ucok A, Gaebel W. (2008). Side effects of atypical antipsychotics: A brief overview. World Psychiatry, 7, 58–62